GO:0160078 negative regulation of lipid droplet fusion: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0160078 (negative regulation of lipid droplet fusion) is a biological process that stops, prevents, or reduces the frequency, rate or extent of lipid droplet fusion.
• Lipid droplet fusion is a thermosensitive process that can be specifically regulated by nuclear hormone receptor pathways, and its negative regulation controls lipid storage and organelle size.
• Cytoskeletal dynamics control lipid droplet movement and fusion, providing a mechanical layer of negative regulation.
• Key proteins such as CIDEC, perilipins, and STX18-ATG14 axis components act as brakes on lipid droplet fusion and turnover.
• Dysregulation of lipid droplet fusion is linked to fatty liver disease, alcohol-associated liver disease, and skeletal muscle fat infiltration.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect causal roles of candidate genes in this process.
Description
Lipid droplets (LDs) are dynamic organelles that store neutral lipids and regulate energy homeostasis. The fusion of LDs is a fundamental process that increases droplet size and can be either promoted or inhibited depending on cellular context. GO:0160078, negative regulation of lipid droplet fusion, refers to any process that stops, prevents, or reduces the frequency, rate or extent of lipid droplet fusion. This regulatory process is critical for maintaining lipid homeostasis and preventing pathological lipid accumulation. Research has shown that lipid droplet fusion is thermosensitive and can be specifically regulated by nuclear hormone receptor pathways, highlighting the existence of dedicated molecular brakes. Understanding these negative regulators is essential for deciphering how cells avoid excessive lipid coalescence and how this goes awry in metabolic diseases. Recent studies have identified cytoskeletal elements as key modulators of LD fusion by controlling LD movement, thereby providing a mechanical mechanism for negative regulation. Moreover, proteins such as CIDEC and the STX18-ATG14 axis have been implicated in restricting LD fusion and turnover, linking this process to liver regeneration and viral evasion. This article synthesizes current knowledge on the negative regulation of lipid droplet fusion, covering its definition, mechanisms, key genes, disease relevance, and research methodologies.
negative regulation of lipid droplet fusion At A Glance
| GO ID | GO:0160078 |
|---|---|
| GO term | negative regulation of lipid droplet fusion |
| Ontology | biological_process |
| Synonym | none |
| Major function | Stops, prevents, or reduces the frequency, rate or extent of lipid droplet fusion |
| Related process | lipid droplet fusion (positive regulation) |
| Cellular context | Cytosol, lipid droplet surface, endoplasmic reticulum |
| Key regulators | Nuclear hormone receptors, cytoskeleton, CIDEC, STX18-ATG14 |
What Is GO:0160078?
According to the Gene Ontology, GO:0160078 (negative regulation of lipid droplet fusion) is defined as any process that stops, prevents, or reduces the frequency, rate or extent of lipid droplet fusion. In other words, it encompasses all molecular and cellular events that act as brakes on the merging of lipid droplets, thereby controlling droplet size, number, and lipid storage capacity. This process is a subcategory of biological regulation and is distinct from positive regulation or the fusion process itself.
Why Is negative regulation of lipid droplet fusion Important in Cell Biology?
The negative regulation of lipid droplet fusion is crucial for maintaining cellular lipid homeostasis and preventing the formation of abnormally large lipid droplets, which are hallmarks of metabolic disorders such as fatty liver disease and lipodystrophies. By controlling droplet size, cells can modulate lipid storage capacity, lipolysis, and signaling. Dysregulation of this process contributes to pathological lipid accumulation in tissues including liver and skeletal muscle, and it also impacts viral replication and liver regeneration. Therefore, understanding the molecular players that negatively regulate LD fusion offers therapeutic targets for metabolic and infectious diseases.
• Prevents excessive lipid droplet growth and lipotoxicity in hepatocytes and adipocytes.
• Regulates energy storage and mobilization in adipose tissue and skeletal muscle.
• Impacts liver regeneration by controlling triglyceride turnover in lipid droplets.
• Modulates host-virus interactions, as coronavirus hijacks lipophagy machinery.
• Influences alcohol-associated fatty liver disease through lipid droplet-associated proteins.
• Controls milk fat synthesis in mammary epithelial cells, relevant to dairy science.
• Provides a thermosensitive switch for lipid storage via nuclear hormone receptors.
• Cytoskeletal regulation of LD movement fine-tunes fusion events.
• Serves as a potential target for treating non-alcoholic fatty liver disease (NAFLD).
• Helps understand basic cell biology of organelle dynamics and membrane fusion.
What Happens During negative regulation of lipid droplet fusion?
Initiation of negative regulation
In simple terms: The cell decides to stop lipid droplets from merging.
Negative regulation of lipid droplet fusion begins with cellular signals that inhibit the fusion machinery. Nuclear hormone receptor pathways can specifically suppress thermosensitive LD fusion, as shown in studies where activation of such receptors reduced fusion events. This step involves sensing lipid status and triggering inhibitory cascades that prevent the tethering and docking of adjacent lipid droplets.
Cytoskeletal control of lipid droplet movement
In simple terms: The cell's skeleton restricts how lipid droplets move and meet each other.
The cytoskeleton plays a critical role in regulating LD fusion by controlling LD movement. Disruption of cytoskeletal dynamics can alter the frequency of LD fusion, indicating that negative regulation involves restraining motor proteins and cytoskeletal tracks that would otherwise bring droplets into contact. This mechanical barrier prevents accidental or excessive fusion.
Molecular brakes at the lipid droplet surface
In simple terms: Special proteins on the droplet surface act as brakes to prevent merging.
Proteins such as CIDEC and perilipins localize to the lipid droplet surface and can inhibit fusion. CIDEC restricts liver regeneration by disturbing lipid droplet triglyceride turnover, effectively acting as a negative regulator of LD fusion and growth. Additionally, the STX18-ATG14 axis regulates lipophagy and can limit LD fusion as part of antiviral defense. These surface proteins create a physical and biochemical barrier to coalescence.
Membrane fusion inhibition and energy barriers
In simple terms: The energy required for membranes to merge is made harder to overcome.
Lipid monolayer fusion requires overcoming an energy barrier from droplet contact to coalescence. Negative regulation can raise this barrier or destabilize fusion intermediates, as suggested by computational studies on the energy pathway of lipid monolayer fusion. By altering lipid composition or protein coating, cells can prevent the spontaneous fusion of droplets.
Integration with lipid turnover and lipophagy
In simple terms: Breaking down lipids also helps prevent droplets from fusing.
Negative regulation of LD fusion is coupled with lipid turnover pathways such as lipophagy. The STX18-ATG14 axis regulates lipophagy, and its manipulation by coronavirus affects LD dynamics. Similarly, BDH1 has a negative effect on lipid metabolism in mammary epithelial cells, likely by promoting lipid utilization and reducing fusion-competent droplets. Thus, enhancing lipid catabolism indirectly reduces fusion.
Key Genes Involved in GO:0160078 negative regulation of lipid droplet fusion
The following genes and proteins have been experimentally implicated in the negative regulation of lipid droplet fusion or closely related processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CIDEC | Inhibits lipid droplet fusion and triglyceride turnover | Liver regeneration, fatty liver disease |
| STX18 | Regulates lipophagy and limits LD fusion | Antiviral defense, coronavirus evasion |
| ATG14 | Component of STX18-ATG14 axis in lipophagy | Autophagy and lipid droplet regulation |
| CircGLIS3 | Inhibits intramuscular adipogenesis and fat infiltration | Skeletal muscle fat infiltration |
| BDH1 | Negative effect on lipid metabolism in mammary cells | Dairy goat milk fat synthesis |
| Perilipin family | Coat lipid droplets and regulate fusion | Alcohol-associated fatty liver disease |
| Nuclear hormone receptors | Thermosensitive regulation of LD fusion | Thermogenesis and lipid storage |
| Cytoskeletal motors (e.g., myosin, kinesin) | Control LD movement and fusion frequency | Cytoskeleton-regulated lipid storage |
| Rab GTPases | Regulate membrane tethering and fusion | General LD fusion machinery |
| SNAREs | Mediate membrane fusion; negative regulators may inhibit | Lipid monolayer fusion energy |
| PLIN1 | Protects LDs from lipolysis and fusion | Lipid droplet stability |
| PLIN2 | Ubiquitous LD coat protein | Liver steatosis |
| PLIN5 | Links LDs to mitochondria | Oxidative tissues |
| FSP27 (CIDEC in humans) | Inhibits LD fusion in adipocytes | Lipodystrophy and obesity |
| Seipin | Restricts LD growth and fusion | Congenital generalized lipodystrophy |
| LDAF1 | Seipin partner in LD formation | LD biogenesis and fusion |
| ORP5/ORP8 | Lipid transfer proteins at ER-LD contacts | LD fusion and lipid homeostasis |
How Is negative regulation of lipid droplet fusion Regulated?
The negative regulation of lipid droplet fusion is controlled by multiple signaling pathways. Nuclear hormone receptor pathways can specifically inhibit thermosensitive LD fusion, suggesting hormonal control. Cytoskeletal dynamics, including actin and microtubule networks, regulate LD movement and thus fusion frequency. Additionally, the STX18-ATG14 axis links lipophagy to LD fusion inhibition, and this axis can be hijacked by coronavirus to evade antiviral effects. Lipid droplet-associated proteins such as CIDEC and perilipins are also regulated at the transcriptional and post-translational levels, influencing their inhibitory capacity. BDH1 expression negatively correlates with lipid metabolism in mammary epithelial cells, indicating metabolic feedback.
negative regulation of lipid droplet fusion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CIDEC | Fatty liver disease, lipodystrophy | Liver-specific knockout mouse |
| STX18 | Coronavirus infection, lipophagy | STX18 knockout cell line |
| CircGLIS3 | Skeletal muscle fat infiltration | CircGLIS3 overexpression in myocytes |
| BDH1 | Mammary gland lipid metabolism | BDH1 knockdown in dairy goat epithelial cells |
| Perilipins | Alcohol-associated fatty liver disease | Plin2 knockout mouse |
Fatty Liver Disease and Alcohol-Associated Liver Disease
Dysregulation of lipid droplet fusion contributes to hepatic steatosis. Proteomic studies of alcohol-associated fatty liver disease have identified alterations in lipid droplet-associated proteins, including those that negatively regulate fusion, suggesting that loss of this brake leads to excessive LD growth and liver injury. CIDEC, a negative regulator of LD fusion, restricts liver regeneration by disturbing triglyceride turnover, and its dysregulation may exacerbate fatty liver.
Skeletal Muscle Fat Infiltration and Metabolic Disorders
CircGLIS3 inhibits intramuscular adipogenesis and alleviates skeletal muscle fat infiltration, a process that involves negative regulation of lipid droplet fusion in muscle cells. This highlights the importance of this GO term in maintaining muscle function and preventing lipotoxicity in metabolic diseases such as obesity and type 2 diabetes.
Viral Infections and Host Defense
Coronavirus hijacks the STX18-ATG14 axis-regulated lipophagy to evade antiviral effects, thereby altering lipid droplet dynamics. Negative regulation of LD fusion is part of the host defense, and viruses can manipulate this process to promote their replication. Understanding this interplay may reveal antiviral targets.
Lipodystrophies and Adipose Tissue Disorders
Mutations in genes that negatively regulate LD fusion, such as CIDEC and seipin, are linked to lipodystrophies characterized by abnormal fat distribution. The inability to properly restrict LD fusion leads to enlarged lipid droplets and impaired adipocyte function, underscoring the clinical relevance of GO:0160078.
From negative regulation of lipid droplet fusion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate LD fusion? | CRISPR knockout of gene X in HepG2 or 3T3-L1 cells |
| Does a point mutation in gene X affect LD fusion? | CRISPR point mutation knock-in in cell lines |
| Does overexpression of gene X reduce LD fusion? | Lentiviral overexpression in adipocytes |
| Does tagged gene X localize to lipid droplets? | CRISPR knock-in of fluorescent tag |
| Is gene X required for thermosensitive LD fusion? | Knockout in brown adipocytes |
| Does gene X regulate lipophagy-linked LD fusion? | Knockout in autophagy-competent cells |
How to Study the negative regulation of lipid droplet fusion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live-cell fluorescence microscopy | LD fusion frequency and size | Real-time regulation by nuclear receptors |
| Proteomics (LC-MS/MS) | LD-associated protein composition | Alcohol-associated fatty liver disease |
| RNA-seq | Transcriptional changes | BDH1 in mammary epithelial cells |
| CRISPR knockout screening | Genes affecting LD fusion | Discovery of negative regulators |
| CRISPR knock-in tagging | Protein localization | LD surface proteins |
| Lipidomics | Lipid species and droplet composition | Fusion energy barriers |
| Western blot | Protein expression levels | CIDEC and perilipin regulation |
| Co-immunoprecipitation | Protein-protein interactions | STX18-ATG14 complex |
Live-cell imaging of lipid droplet fusion
Fluorescence microscopy with lipid droplet dyes (e.g., BODIPY) allows real-time visualization of fusion events. This method can quantify the frequency and rate of LD fusion and assess the impact of negative regulators.
Proteomics of lipid droplet-associated proteins
Isolation of lipid droplets followed by mass spectrometry identifies proteins enriched on LDs, including negative regulators. This approach has been used in alcohol-associated fatty liver disease to uncover disease-related changes.
Transcriptomics and RNA-seq
RNA sequencing reveals gene expression changes in models of altered LD fusion. For example, transcriptome analysis identified BDH1 as a negative regulator of lipid metabolism in mammary epithelial cells.
CRISPR screening for regulators of LD fusion
Genome-wide CRISPR knockout or activation screens coupled with imaging-based readouts can identify novel negative regulators of LD fusion. This unbiased approach is powerful for discovering genes like CIDEC and STX18.
How CRISPR Can Be Used to Study GO:0160078 negative regulation of lipid droplet fusion
Knockout
CRISPR knockout of candidate negative regulators (e.g., CIDEC, STX18) in cell lines or animal models can confirm their role in suppressing LD fusion. Loss of function typically leads to increased LD fusion and larger droplets, as shown for CIDEC in liver regeneration studies.
Point Mutation
Introducing specific point mutations in genes like seipin or CIDEC can dissect functional domains required for negative regulation of LD fusion. This approach helps distinguish between fusion inhibition and other functions.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) into endogenous loci allows real-time tracking of negative regulator localization to lipid droplets. This can reveal dynamic changes during fusion events.
Overexpression
Overexpression of candidate genes such as CircGLIS3 or BDH1 can test whether increased levels enhance negative regulation of LD fusion and reduce lipid accumulation, as demonstrated in skeletal muscle and mammary cells.
How EDITGENE Supports negative regulation of lipid droplet fusion Research
Researchers studying negative regulation of lipid droplet fusion-related genes often need to determine whether a candidate gene is causally involved in suppressing droplet coalescence or is merely correlated with lipid storage changes. EDITGENE provides comprehensive CRISPR-based services to establish causality and dissect molecular mechanisms.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lipid droplet fusion research.
Frequently Asked Questions About negative regulation of lipid droplet fusion
What is negative regulation of lipid droplet fusion?
It is a biological process (GO:0160078) that stops, prevents, or reduces the frequency, rate or extent of lipid droplet fusion, thereby controlling lipid droplet size and lipid storage.
What genes are involved in negative regulation of lipid droplet fusion?
Key genes include CIDEC, STX18, ATG14, CircGLIS3, BDH1, and perilipins, as well as nuclear hormone receptors and cytoskeletal components.
How is lipid droplet fusion negatively regulated?
Through molecular brakes such as CIDEC and perilipins on the droplet surface, cytoskeletal restriction of droplet movement, and lipophagy-mediated lipid turnover.
Why is negative regulation of lipid droplet fusion important?
It prevents excessive lipid droplet growth and lipotoxicity, and its dysregulation is linked to fatty liver disease, skeletal muscle fat infiltration, and viral infections.
What diseases are associated with defective negative regulation of lipid droplet fusion?
Fatty liver disease, alcohol-associated liver disease, lipodystrophies, skeletal muscle fat infiltration, and altered host-virus interactions.
How can CRISPR be used to study negative regulation of lipid droplet fusion?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of candidate genes in lipid droplet fusion assays.
What methods are used to measure lipid droplet fusion?
Live-cell fluorescence microscopy, proteomics, RNA-seq, and CRISPR screens are commonly used to quantify fusion events and identify regulators.
Is lipid droplet fusion thermosensitive?
Yes, studies have shown that lipid droplet fusion can be specifically regulated by nuclear hormone receptor pathways in a thermosensitive manner.
What is the role of CIDEC in lipid droplet fusion?
CIDEC (also known as FSP27) inhibits lipid droplet fusion and restricts liver regeneration by disturbing triglyceride turnover.
How does coronavirus affect lipid droplet fusion?
Coronavirus hijacks the STX18-ATG14 axis-regulated lipophagy to evade antiviral effects, thereby altering lipid droplet dynamics and fusion.
Conclusion
The negative regulation of lipid droplet fusion (GO:0160078) is a vital cellular process that prevents excessive lipid coalescence and maintains metabolic homeostasis. Key regulators such as CIDEC, STX18-ATG14, and cytoskeletal elements provide molecular brakes that are essential for health. Dysregulation of this process contributes to fatty liver disease, muscle fat infiltration, and viral pathogenesis. Continued research using CRISPR models and advanced imaging will uncover new therapeutic targets. EDITGENE offers comprehensive services to support these investigations.
References
- 1. Yu S et al.. 2025. CircGLIS3 Inhibits Intramuscular Adipogenesis and Alleviates Skeletal Muscle Fat Infiltration.. J Cachexia Sarcopenia Muscle 16(4):e70009 PMID: 40735833
- 2. Li S et al.. 2017. Specific regulation of thermosensitive lipid droplet fusion by a nuclear hormone receptor pathway.. Proc Natl Acad Sci U S A 114(33):8841-8846 PMID: 28760992
- 3. Molotkovsky RJ et al.. 2025. Energy Pathway of Lipid Monolayer Fusion: From Droplet Contact to Coalescence.. J Phys Chem B 129(27):7010-7021 PMID: 40566901
- 4. Liang Y et al.. 2025. Cytoskeleton regulates lipid droplet fusion and lipid storage by controlling lipid droplet movement.. Biochim Biophys Acta Mol Cell Biol Lipids 1870(4):159610 PMID: 40189192
- 5. Ouyang F et al.. 2026. CIDEC Restricts Liver Regeneration by Disturbing Lipid Droplet Triglyceride Turnover.. Adv Sci (Weinh) 13(3):e07048 PMID: 41255220
- 6. Perumal SK et al.. 2024. Lipid droplet-associated proteins in alcohol-associated fatty liver disease: A proteomic approach.. Alcohol Clin Exp Res (Hoboken) 48(11):2010-2021 PMID: 39414381
- 7. Yuan Z et al.. 2024. Coronavirus hijacks STX18-ATG14 axis-regulated lipophagy to evade an anti-viral effect.. Autophagy 20(8):1895-1896 PMID: 38477940
- 8. Ni M et al.. 2025. BDH1 identified by transcriptome has a negative effect on lipid metabolism in mammary epithelial cells of dairy goats.. BMC Genomics 26(1):66 PMID: 39856554
